SHORTWAVE LIFE SCIENCES PLC

("Shortwave" or "the Company")

6^th of November 2025

Patent Application Publication

For Buccal film formation

Shortwave Life Sciences PLC (PSY), listed on the Aquis Stock Exchange Growth Market, the UK's leading healthcare company focused on developing innovative treatments for anorexia nervosa, is pleased to announce the publication of its patent application for its mucoadhesive composition and method for administration of pharmaceutically effective agents, Buccal film formation.

Shortwave has led the development of delivery and administration methods for novel drug combinations, targeting unmet critical needs in mental health care. Shortwave's administration methods are tailored to the unique needs and challenges of its patient populations, while also offering additional advantages that may be relevant to other therapeutic areas.

Our first drug delivery product is a thin buccal film with mucoadhesive absorption of a psilocybin-based API combination designed for anorexia nervosa patients.

The film enables fast onset and superior absorption of the drug, bypassing gut and liver degradation, while allowing precise control of low active-compound doses, thereby enhancing safety and meeting regulatory requirements.

It is customized to address the metabolic challenges of anorexia patients,

and to meet the specific needs of this population, which often experiences difficulty swallowing.

Shortwave's buccal film has received a stellar International PCT Preliminary Report on Patentability acknowledging all of its 19 claims as Novel, Non-Obvious (Inventive Step) and Industrially Applicable.

Shortwave's mucoadhesive buccal film for the administration of its psilocybin-based combination drug product had completed its 2-year development in 2023, having current stability of 9 months.

Buccal Highlights:

The film is polymer-based and incorporates at least two active agents, both water-insoluble and water-soluble. It enables high loading of multiple active ingredients and has been specifically developed to prevent any interaction between the APIs. The ratio of active ingredients remains stable throughout the product's life cycle, while the mucoadhesive mechanism allows for rapid drug release.

Film IP:

The invention entered the national phase in November 2024.
Shortwave's buccal film received a highly favorable opinion from the PCT committee, acknowledging all 19 claims as novel, inventive, and industrially applicable.
The above-referenced patent application was published by the USPTO on 11 September 2025 under publication number US-2025-0281399-A1.

Rolf Gerritsen comments:

 "I am delighted with the progress we are making with our core business and look forward to finalising the application and exploring commercial partnerships on the back of it."

About Shortwave Life Sciences:

Shortwave Life Sciences is a developer of breakthrough therapies addressing unmet medical needs in mental health. The Company is committed to the advancement of innovative solutions through drug development, with a mission to pioneer breakthrough therapies that transform the landscape of mental health care. With a team of dedicated experts and a commitment to innovation, Shortwave Life Sciences is uniquely positioned to introduce and develop solutions for the complex challenges of mental health disorders worldwide.

The Directors of the Company accept responsibility for the contents of this announcement.

For media inquiries, please contact:

Enquiries:

Company:

Rolf Gerritsen

+44 20383 87621

AlbR Capital Limited:

Corporate Adviser:

+ 44 (0) 20 7469 0930